351. de Boer, M.; Klein, A.; Hossle, J.-P.; Seger, R.; Corbeel, L.; Weening, R.S.; Roos, D. Cytochrome b558-negative, autosomal recessive chronic granulomatous disease: Two new mutations in the cytochrome b558 light chain of the NADPH oxidase (p22-phox). *Am. J. Hum. Genet.* **1992**, *51*, 1127–1135.

352. Roos, D.; Kuhns, D.B.; Maddalena, A.; Bustamante, J.; Kannengiesser, C.; de Boer, M.; van Leeuwen, K.; Köker, M.Y.; Wolach, B.; Roesler, J.; et al. Hematologically important mutations: The autosomal recessive forms of chronic granulomatous disease (second update). *Blood Cells Mol. Dis.* **2010**, *44*, 291–299. [CrossRef]

353. van den Berg, J.M.; van Koppen, E.; Ahlin, A.; Belohradsky, B.; Bernatowska, E.; Corbeel, L.; Español, T.; Fischer, A.; Kurenko-Deptuch, M.; Mouy, R.; et al. Chronic Granulomatous Disease: The European Experience. *PLoS ONE* **2009**, *4*, e5234. [CrossRef]

354. Popa-Wagner, A.; Mitran, S.; Sivanesan, S.; Chang, E.; Buga, A.M. ROS and brain diseases: The good, the bad, and the ugly. *Oxid. Med. Cell. Longev.* **2013**, *2013*, 963520. [CrossRef]

355. Sorce, S.; Krause, K.H. NOX enzymes in the central nervous system: From signaling to disease. *Antioxid. Redox Signal* **2009**, *11*, 2481–2504. [CrossRef]

356. Chéret, C.; Gervais, A.; Lelli, A.; Colin, C.; Amar, L.; Ravassard, P.; Mallet, J.; Cumano, A.; Krause, K.H.; Mallat, M. Neurotoxic activation of microglia is promoted by a nox1-dependent NADPH oxidase. *J. Neurosci.* **2008**, *12*, 12039–12051. [CrossRef] [PubMed]

357. Li, B.; Bedard, K.; Sorce, S.; Hinz, B.; Dubois-Dauphin, M.; Krause, K.H. NOX4 expression in human microglia leads to constitutive generation of reactive oxygen species and to constitutive IL-6 expression. *J. Innate Immun.* **2009**, *1*, 570–581. [CrossRef] [PubMed]

358. Yao, H.; Ago, T.; Kitazono, T.; Nabika, T. NADPH Oxidase-Related Pathophysiology in Experimental Models of Stroke. *Int. J. Mol. Sci.* **2017**, *18*, 2123. [CrossRef] [PubMed]

359. Hernandes, M.S.; Café-Mendes, C.C.; Britto, L.R.G. NADPH oxidase and the degeneration of dopaminergic neurons in parkinsonian mice. *Oxid. Med. Cell. Longev.* **2013**, *2013*, 157857. [CrossRef]

360. Przedborski, S.; Vila, M. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: A tool to explore the pathogenesis of Parkinson's disease. *Ann. N. Y. Acad. Sci.* **2003**, *991*, 189–198. [CrossRef]

361. Meredith, G.E.; Rademacher, D.J. MPTP mouse models of Parkinson's disease: An update. *J. Parkinsons Dis.* **2011**, *1*, 19–33. [CrossRef]

362. George, J.L.; Mok, S.; Moses, D.; Wilkins, S.; Bush, A.I.; Cherny, R.A.; Finkelstein, D.I. Targeting the Progression of Parkinson's Disease. *Curr. Neuropharmacol.* **2009**, *7*, 9–36. [CrossRef] [PubMed]

363. Huh, S.H.; Chung, Y.C.; Piao, Y.; Jin, M.Y.; Son, H.J.; Yoon, N.S.; Hong, J.Y.; Pak, Y.K.; Kim, Y.S.; Hong, J.K.; et al. Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson's disease. *J. Immunol.* **2011**, *187*, 960–969. [CrossRef] [PubMed]

364. Dias, V.; Junn, E.; Mouradian, M.M. The role of oxidative stress in Parkinson's disease. *J. Parkinsons Dis.* **2013**, *3*, 461–491. [CrossRef]

365. Guo, J.; Zhao, X.; Li, Y.; Li, G.; Liu, X. Damage to dopaminergic neurons by oxidative stress in Parkinson's disease. *Int. J. Mol. Med.* **2018**, *41*, 1817–1825. [CrossRef]

366. Belarbi, K.; Cuvelier, E.; Destée, A.; Gressier, B.; Chartier-Harlin, M.-C. NADPH oxidases in Parkinson's disease: A systematic review. *Mol. Neurodegener.* **2017**, *12*, 84. [CrossRef]

367. Rodriguez-Pallares, J.; Rey, P.; Parga, J.; Muñoz, A.; Guerra, M.; Labandeira-Garcia, J. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. *Neurobiol. Dis.* **2008**, *31*, 58–73. [CrossRef]

368. Kim, S.; Hwang, J.; Lee, W.H.; Hwang, D.Y.; Suk, K. Role of protein kinase in paraquat-induced glial cell death. *J. Neurosci. Res.* **2008**, *86*, 2062–2070. [CrossRef]

369. Shimohama, S.; Tanino, H.; Kawakami, N.; Okamura, N.; Kodama, H.; Yamaguchi, T.; Hayakawa, T.; Nunomura, A.; Chiba, S.; Perry, G.; et al. Activation of NADPH Oxidase in Alzheimer's Disease Brains. *Biochem. Biophys. Res. Commun.* **2000**, *273*, 5–9. [CrossRef]

370. Park, L.; Zhou, P.; Pitstick, R.; Capone, C.; Anrather, J.; Norris, E.H.; Younkin, L.; Younkin, S.; Carlson, G.; McEwen, B.S.; et al. Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 1347–1352. [CrossRef]

371. Gamba, P.; Leonarduzzi, G.; Tamagno, E.; Guglielmotto, M.; Testa, G.; Sottero, B.; Gargiulo, S.; Biasi, F.; Mauro, A.; Viña, J.; et al. Interaction between 24-hydroxycholesterol, oxidative stress, and amyloid-b in amplifying neuronal damage in Alzheimer's disease: Three partners in crime. *Aging Cell* **2011**, *10*, 403–417. [CrossRef]

372. Bruce-Keller, A.J.; Gupta, S.; Knight, A.G.; Beckett, T.L.; McMullen, J.M.; Davis, P.R.; Murphy, M.P.; van Eldik, L.J.; Clair, D.S.; Keller, J.N. Cognitive Impairment in Humanized APPxPS1 Mice is Linked to Aβ1-42 and NOX Activation. *Neurobiol. Dis.* **2011**, *44*, 317–326. [CrossRef] [PubMed]

373. Akhter, H.; Katre, A.; Li, L.; Liu, X.; Liu, R.M. Therapeutic potential and anti-amyloidosis mechanisms of tert-butylhydroquinone for Alzheimer's disease. *J. Alzheimers Dis.* **2011**, *26*, 767–778. [CrossRef]

374. Choi, D.H.; Lee, K.H.; Kim, J.H.; Seo, J.H.; Kim, H.Y.; Shin, C.Y.; Han, J.S.; Han, S.H.; Kim, Y.S.; Lee, J. NADPH Oxidase 1, a Novel Molecular Source of ROS in Hippocampal Neuronal Death in Vascular Dementia. *Antioxid. Redox Signal.* **2014**, *21*, 533–550. [CrossRef]

375. de la Monte, S.M.; Wands, J.R. Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. *J. Alzheimers Dis.* **2006**, *9*, 167–181. [CrossRef]
376. Hernandes, M.S.; Britto, L.R.G. NADPH Oxidase and Neurodegeneration. *Curr. Neuropharmacol.* **2012**, *10*, 321–327. [CrossRef]

377. Meitzler, J.L.; Antony, S.; Wu, Y.; Juhasz, A.; Liu, H.; Jiang, G.; Lu, J.; Roy, K.; Doroshow, J.H. NADPH Oxidases: A Perspective on Reactive Oxygen Species Production in Tumor Biology. *Antioxid. Redox Signal.* **2014**, *20*, 2873–2888. [CrossRef]

378. Juhasz, A.; Ge, Y.; Markel, S.; Chiu, A.; Matsumoto, L.; van Balgooy, J.; Roy, K.; Doroshow, J.H. Expression of NADPH oxidase homologues and accessory genes in human cancer cell lines, tumours and adjacent normal tissues. *Free Radic. Res.* **2009**, *43*, 523–532. [CrossRef] [PubMed]

379. Day, R.M.; Suzuki, Y.J. Cell Proliferation, Reactive Oxygen and Cellular Glutathione. *Dose Response* **2005**, *3*, 425–442. [CrossRef]

380. Wang, P.; Shi, Q.; Deng, W.-H.; Yu, J.; Zuo, T.; Mei, F.C.; Wang, W.X. Relationship between expression of NADPH oxidase 2 and invasion and prognosis of human gastric cancer. *World J. Gastroenterol.* **2015**, *21*, 6271–6279. [CrossRef]

381. You, X.; Ma, M.; Hou, G.; Hu, Y.; Shi, X. Gene expression and prognosis of NOX family members in gastric cancer. *Onco Targets Ther.* **2018**, *11*, 3065–3074. [CrossRef] [PubMed]

382. Ren, J.G.; Xia, H.L.; Just, T.; Dai, Y.R. Hydroxyl radical-induced apoptosis in human tumor cells is associated with telomere shortening but not telomerase inhibition and caspase activation. *FEBS Lett.* **2001**, *488*, 123–132. [CrossRef]

383. Matsura, T.; Kai, M.; Fujii, Y.; Ito, H.; Yamada, K. Hydrogen peroxide-induced apoptosis in HL-60 cells requires caspase-3 activation. *Free Radic. Res.* **1999**, *30*, 73–83. [CrossRef]

384. Simizu, S.; Takada, M.; Umezawa, K.; Imoto, M. Requirement of Caspase-3(-like) Protease-mediated Hydrogen Peroxide Production for Apoptosis Induced by Various Anticancer Drugs. *J. Biol. Chem.* **1998**, *273*, 26900–26907. [CrossRef]

385. Skonieczna, M.; Hejmo, T.; Poterala-Hejmo, A.; Cieslar-Pobuda, A.; Buldak, R.J. NADPH Oxidases: Insights into Selected Functions and Mechanisms of Action in Cancer and Stem Cells. *Oxid. Med. Cell. Longev.* **2017**, *2017*. [CrossRef]

386. Limoli, C.L.; Giedzinski, E. Induction of chromosomal instability by chronic oxidative stress. *Neoplasia* **2003**, *5*, 339–346. [CrossRef]

387. Hunt, C.R.; Sim, J.E.; Sullivan, S.J.; Featherstone, T.; Golden, W.; Von Kapp-Herr, C.; Hock, R.A.; Gomez, R.A.; Parsian, A.J.; Spitz, D.R. Genomic instability and catalase gene amplification induced by chronic exposure to oxidative stress. *Cancer Res.* **1998**, *58*, 3986–3992.

388. Limoli, C.L.; Hartmann, A.; Shephard, L.; Yang, C.R.; Boothman, D.A.; Bartholomew, J.; Morgan, W.F. Apoptosis, reproductive failure, and oxidative stress in Chinese hamster ovary cells with compromised genomic integrity. *Cancer Res.* **1998**, *58*, 3712–3718.

389. Clutton, S.M.; Townsend, K.M.S.; Walker, C.; Ansell, J.D.; Wright, E.G. Radiation-induced genomic instability and persisting oxidative stress in primary bone marrow cultures. *Carcinogenesis* **1996**, *17*, 1633–1639. [CrossRef]

390. Graham, K.; Kulawiec, M.; Owens, K.; Li, X.; Desouki, M.; Chandra, D.; Singh, K. NADPH oxidase 4 is an oncoprotein localized to mitochondria. *Cancer Biol.* **2010**, *10*, 223–231. [CrossRef]

391. Kartha, G.; Moshal, K.; Sen, U.; Joshua, I.; Tyagi, N.; Steed, M.; Tyagi, S. Renal mitochondrial damage and protein modification in type-2 diabetes. *Acta Diabetol.* **2008**, *45*, 75–81. [CrossRef]

392. Spencer, N.Y.; Yan, Z.; Boudreau, R.L.; Zhang, Y.; Luo, M.; Li, Q.; Tian, X.; Shah, A.M.; Davisson, R.L.; Davidson, B.; et al. Control of Hepatic Nuclear Superoxide Production by Glucose 6-Phosphate Dehydrogenase and NADPH Oxidase-4. *J. Biol. Chem.* **2011**, *286*, 8977–8987. [CrossRef] [PubMed]

393. Salmeen, A.; Park, B.; Meyer, T. The NADPH oxidases NOX4 and DUOX2 regulate cell cycle entry via a p53-dependent pathway. *Oncogene* **2010**, *29*, 4473–4484. [CrossRef]

394. Eid, A.A.; Ford, B.M.; Block, K.; Kasinath, B.S.; Gorin, Y.; Ghosh-Choudhury, G.; Barnes, J.L.; Abboud, H.E. AMP-activated protein kinase (AMPK) negatively regulates Nox4-dependent activation of p53 and epithelial cell apoptosis in diabetes. *J. Biol. Chem.* **2010**, *285*, 37503–37512. [CrossRef]

395. Boudreau, H.E.; Casterline, B.W.; Burke, D.J.; Leto, T.L. Wild-type and mutant p53 differentially regulate NADPH oxidase 4 in TGF-beta-mediated migration of human lung and breast epithelial cells. *Br. J. Cancer* **2014**, *110*, 2569–2582. [CrossRef]

396. Vaziri, H.; Dessain, S.K.; Eaton, E.N.; Imai, S.I.; Frye, R.A.; Pandita, T.K.; Guarente, L.; Weinberg, R.A. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. *Cell* **2001**, *107*, 149–159. [CrossRef]

397. Laurent, E.; McCoy III, J.W.; Macina, R.A.; Liu, W.; Cheng, G.; Robine, S.; Papkoff, J.; Lambeth, J.D. Nox1 is over-expressed in human colon cancers and correlates with activating mutations in K-Ras. *Int. J. Cancer* **2008**, *123*, 100–107. [CrossRef]

398. Thiery, J.P. Epithelial-mesenchymal transitions in development and pathologies. *Curr. Opin Cell. Biol.* **2003**, *15*, 740–746. [CrossRef]

399. Leong, H.S.; Robertson, A.E.; Stoletov, K.; Chin, C.A.; Chien, A.E.; Hague, M.N.; Ablack, A.; Carmine-Simmen, K.; McPherson, V.A.; Postenka, C.O.; et al. Invadopodia Are Required for Cancer Cell Extravasation and Are a Therapeutic Target for Metastasis. *Cell Rep.* **2014**, *8*, 1558–1570. [CrossRef] [PubMed]

400. Diaz, B.; Shani, G.; Pass, D.A.I.; Quintavalle, M.; Courtneidge, S.A. Tks5-dependent, Nox-mediated Generation of Reactive Oxygen Species is Necessary for Invadopodia Formation. *Sci. Signal.* **2009**, *2*, 1–15. [CrossRef]

401. van Zijl, F.; Krupitza, G.; Mikulits, W. Initial steps of metastasis: Cell invasion and endothelial transmigration. *Mutat. Res.* **2011**, *728*, 23–34. [CrossRef]

402. Paz, H.; Pathak, N.; Yang, J. Invading one step at a time: The role of invadopodia in tumor metastasis. *Oncogene* **2014**, *33*, 4193–4202. [CrossRef]

403. Lock, P.; Abram, C.L.; Gibson, T.; Courtneidge, S.A. A new method for isolating tyrosine kinase substrates used to identify fish, an SH3 and PX domain-containing protein, and Src substrate. *EMBO J.* **1998**, *17*, 4346–4357. [CrossRef]
404. Gianni, D.; Diaz, B.; Taulet, N.; Fowler, B.; Courtneidge, S.; Bokoch, G. Novel p47(phox)-related organizers regulate localized NADPH oxidase 1 (Nox1) activity. *Sci. Signal.* **2009**, *2*, ra54. [CrossRef]

405. Seals, D.F.; Azucena, E.F.J.; Pass, I.; Tesfay, L.; Gordon, R.; Woodrow, M.; Resau, J.H.; Courtneidge, S.A. The adaptor protein Tks5/Fish is required for podosome formation and function, and for the protease-driven invasion of cancer cells. *Cancer Cell* **2005**, *7*, 155-165. [CrossRef]

406. Revach, O.Y.; Sandler, O.; Samuels, Y.; Geiger, B. Cross-talk between receptor tyrosine kinases AXL and ERBB3 regulates invadopodia formation in melanoma cells. *Cancer Res.* **2019**, *79*, 2634-2648. [CrossRef]

407. Liu, X.; Pei, C.; Yan, S.; Liu, G.; Liu, G.; Chen, W.; Cui, Y.; Liu, Y. NADPH oxidase 1-dependent ROS is crucial for TLR4 signaling to promote tumor metastasis of non-small cell lung cancer. *Tumour Biol.* **2015**, *36*, 1493-1502. [CrossRef] [PubMed]

408. Pei, J.; Lou, Y.; Zhong, R.; Han, B. MMP9 activation triggered by epidermal growth factor induced FoxO1 nuclear exclusion in nonsmall cell lung cancer. *Tumour Biol.* **2014**, *35*, 6673-6678. [CrossRef]

409. Choi, Y.H.; Burdick, M.D.; Strieter, B.A.; Mehrad, B.; Strieter, R.M. CXCR4, but not CXCR7, discriminates metastatic behavior in nonsmall cell lung cancer cells. *Mol. Cancer Res.* **2014**, *12*, 38-47. [CrossRef]

410. O'Leary, D.P.; Bhatt, L.; Woolley, J.F.; Gough, D.R.; Wang, J.H.; Cotter, T.G.; Redmond, H.P. TLR-4 signalling accelerates colon cancer cell adhesion via NF-κB mediated transcriptional up-regulation of Nox-1. *PLoS ONE* **2012**, *7*, e44176. [CrossRef]

411. Huang, H.S.; Liu, Z.M.; Chen, P.C.; Tseng, H.Y.; Yeh, B.W. TG-interacting factor-induced superoxide production from NADPH oxidase contributes to the migration/invasion of urothelial carcinoma. *Free Radic. Biol. Med.* **2012**, *53*, 769-778. [CrossRef] [PubMed]

412. Nishida, N.; Yano, H.; Nishida, T.; Kamura, T.; Kojiro, M. Angiogenesis in cancer. *Vasc. Health Risk Manag.* **2006**, *2*, 213-219. [CrossRef] [PubMed]

413. Helfinger, V.; Henke, N.; Harenkamp, S.; Walter, M.; Epah, J.; Penski, C.; Mittelbronn, M.; Schröder, K. The NADPH oxidase Nox4 mediates tumour angiogenesis. *Acta Physiol.* **2016**, *216*, 435-446. [CrossRef]

414. Jung, S.N.; Yang, W.K.; Kim, J.; Kim, H.S.; Kim, E.J.; Yun, H.; Park, H.; Kim, S.S.; Choe, W.; Kang, I.; et al. Reactive oxygen species stabilize hypoxia-inducible factor-1 alpha protein and stimulate transcriptional activity via AMP-activated protein kinase in DU145 human prostate cancer cells. *Carcinogenesis* **2008**, *29*, 713-721. [CrossRef]

415. Xia, C.; Meng, Q.; Liu, L.Z.; Rojanasakul, Y.; Wang, X.R.; Jiang, B.H. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. *Cancer Res.* **2007**, *67*, 10823-10830. [CrossRef]

416. Arbiser, J.L.; Petros, J.; Klafter, R.; Govindajaran, B.; McLaughlin, E.R.; Brown, L.F.; Cohen, C.; Moses, M.; Kilroy, S.; Arnold, R.S.; et al. Reactive oxygen generated by Nox1 triggers the angiogenic switch. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 715-720. [CrossRef]

417. Karar, J.; Maity, A. PI3K/AKT/mTOR pathway in angiogenesis. *Front. Mol. Neurosci.* **2011**, *4*, 51. [CrossRef]

418. Block, K.; Gorin, Y. Aiding and abetting roles of NOX oxidases in cellular transformation. *Nat. Rev. Cancer* **2012**, *12*, 627-637. [CrossRef]

419. Govindarajan, B.; Sligh, J.; Vincent, B.; Li, M.; Canter, J.; Nickoloff, B.; Rodenburg, R.; Smeitink, J.; Oberley, L.; Zhang, Y.; et al. Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. *J. Clin. Investig.* **2007**, *117*, 719-729. [CrossRef] [PubMed]

420. Pozzi, A.; Ibanez, M.R.; Gatica, A.E.; Yang, S.; Wei, S.; Mei, S.; Falck, J.R.; Capdevila, J.H. Peroxisomal proliferator-activated receptor-α-dependent inhibition of endothelial cell proliferation and tumorigenesis. *J. Biol. Chem.* **2007**, *282*, 17685-17695. [CrossRef] [PubMed]

421. Banskota, S.; Gautam, J.; Regmi, S.C.; Gurung, P.; Park, M.H.; Kim, S.J.; Nam, T.G.; Jeong, B.S.; Kim, J.A. BJ-1108, a 6-amino-2,4,5-trimethylpyridin-3-ol analog, inhibits serotonininduced angiogenesis and tumor growth through PI3K/NOX pathway. *PLoS ONE* **2016**, *11*, e0148133. [CrossRef] [PubMed]

422. Konior, A.; Schramm, A.; Czesnikiewicz-Guzik, M.; Guzik, T.J. NADPH Oxidases in Vascular Pathology. *Antioxid. Redox Signal.* **2014**, *20*, 2794-2814. [CrossRef]

423. Zhang, Y.; Murugesan, P.; Huang, K.; Cai, H. NADPH oxidases and oxidase crosstalk in cardiovascular diseases: Novel therapeutic targets. *Nat. Rev. Cardiol.* **2020**, *17*, 170-194. [CrossRef]

424. Burtenshaw, D.; Hakimjavadi, R.; Redmond, E.; Cahill, P. Nox Reactive Oxygen Species and Regulation of Vascular Cell Fate. *Antioxidants* **2017**, *6*, 90. [CrossRef] [PubMed]

425. de Keulenaer, G.W.; Alexander, R.W.; Ushio-Fukai, M.; Ishizaka, N.; Griendling, K.K. Tumour necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle. *Biochem. J.* **1998**, *329*, 653-657. [CrossRef] [PubMed]

426. Brandes, R.P.; Viedt, C.; Nguyen, K.; Beer, S.; Kreuzer, J.; Busse, R.; Gorlach, A. Thrombin-induced MCP-1 expression involves activation of the p22phox-containing NADPH oxidase in human vascular smooth muscle cells. *Thromb. Haemost.* **2001**, *85*, 1104-1110. [PubMed]

427. Jansen, F.; Yang, X.; Franklin, B.S.; Hoelscher, M.; Schmitz, T.; Bedorf, J.; Nickenig, G.; Werner, N. High glucose condition increases NADPH oxidase activity in endothelial microparticles that promote vascular inflammation. *Cardiovasc. Res.* **2013**, *98*, 94-106. [CrossRef]

428. Brandes, R.P. Vascular Functions of NADPH Oxidases. *Hypertension* **2010**, *56*, 17-21. [CrossRef] [PubMed]

429. Rajagopalan, S.; Kurz, S.; Münzel, T.; Tarpey, M.; Freeman, B.A.; Griendling, K.K.; Harrison, D.G. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. *J. Clin. Investig.* **1996**, *97*, 1916-1923. [CrossRef]
430. Guzik, T.J.; Mussa, S.; Gastaldi, D.; Sadowski, J.; Ratnatunga, C.; Pillai, R.; Channon, K.M. Mechanisms of increased vascular superoxide production in human diabetes mellitus: Role of NAD(P)H oxidase and endothelial nitric oxide synthase. *Circulation* **2002**, *105*, 1656–1662. [CrossRef] [PubMed]

431. Dikalova, A.; Clempus, R.; Lassègue, B.; Cheng, G.; McCoy, J.; Dikalov, S.; Martin, A.S.; Lyle, A.; Weber, D.S.; Weiss, D.; et al. Nox1 Overexpression Potentiates Angiotensin II-Induced Hypertension and Vascular Smooth Muscle Hypertrophy in Transgenic Mice. *Circulation* **2005**, *112*, 2668–2676. [CrossRef]

432. Landmesser, U.; Cai, H.; Dikalov, S.; McCann, L.; Hwang, J.; Jo, H.; Holland, S.M.; Harrison, D.G. Role of p47phox in Vascular Oxidative Stress and Hypertension Caused by Angiotensin II. *Hypertension* **2002**, *40*, 511–515. [CrossRef] [PubMed]

433. Landmesser, U.; Dikalov, S.; Price, S.R. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. *J. Clin. Investig.* **2003**, *111*, 1201–1209. [CrossRef]

434. Schröder, K.; Zhang, M.; Benkhoff, S.; Mieth, A.; Pliquett, R.; Kosowski, J.; Kruse, C.; Luedike, P.; Michaelis, U.R.; Weissmann, N.; et al. Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. *Circ. Res.* **2012**, *110*, 1217–1225. [CrossRef]

435. Ray, R.; Murdoch, C.E.; Wang, M.; Santos, C.X. Endothelial Nox4 NADPH Oxidase Enhances Vasodilatation and Reduces Blood Pressure In Vivo. *Arterioscler. Thromb. Vasc. Biol.* **2011**, *31*, 1368–1376. [CrossRef]

436. Quesada, I.M.; Lucero, A.; Amaya, C.; Meijles, D.N.; Cifuentes, M.E.; Pagano, P.J.; Castro, C. Selective inactivation of NADPH oxidase 2 causes regression of vascularization and the size and stability of atherosclerotic plaques. *Atherosclerosis* **2015**, *242*, 469–475. [CrossRef]

437. Khatri, J.J.; Johnson, C.; Magid, R.; Lessner, S.M. Vascular Oxidant Stress Enhances Progression and Angiogenesis of Experimental Atheroma. *Circulation* **2004**, *109*, 520–525. [CrossRef]

438. Meyer, J.W.; Schmitt, M.E. A central role for the endothelial NADPH oxidase in atherosclerosis. *FEBS Lett.* **2000**, *472*, 1–4. [CrossRef]

439. Hink, U.; Li, H.; Mollnau, H.; Oelze, M.; Matheis, E.; Hartmann, M.; Skatchkov, M.; Thaiss, F.; Stahl, R.A.; Warnholtz, A.; et al. Mechanisms Underlying Endothelial Dysfunction in Diabetes Mellitus. *Circ. Res.* **2001**, *8*, E14–E22. [CrossRef]

440. Guzik, T.J.; West, N.E.J.; Black, E.; McDonald, D.; Ratnatunga, C.; Pillai, R.; Channon, K.M. Vascular Superoxide Production by NAD(P)H Oxidase. Association With Endothelial Dysfunction and Clinical Risk Factors. *Circ. Res.* **2000**, *86*, e85–e90. [PubMed]

441. Ding, H.; Hashem, M.; Triggle, C. Increased oxidative stress in the streptozotocin-induced diabetic apoE-deficient mouse: Changes in expression of NADPH oxidase subunits and eNOS. *Eur. J. Pharm.* **2007**, *561*, 121–128. [CrossRef]

442. Liang, C.F.; Liu, J.T.C.; Wang, Y.; Xu, A.; Vanhoutte, P.M. Toll-Like Receptor 4 Mutation Protects Obese Mice Against Endothelial Dysfunction by Decreasing NADPH Oxidase Isoforms 1 and 4. *Arterioscler. Thromb. Vasc. Biol.* **2013**, *33*, 777–784. [CrossRef]

443. Gray, S.P.; di Marco, E.; Okabe, J.; Szyndralewiez, C.; Heitz, F.; Montezano, A.C.; de Haan, J.B.; Koulis, C.; El-Osta, A.; Andrews, K.L.; et al. NADPH Oxidase 1 Plays a Key Role in Diabetes Mellitus–Accelerated Atherosclerosis. *Circulation* **2013**, *127*, 1888–1902. [CrossRef]

444. Augsburger, F.; Filippova, A.; Rasti, D.; Seredenina, T.; Lam, M.; Maghzal, G.; Mahiout, Z.; Jansen-Dürr, P.; Knaus, U.G.; Doroshow, J.; et al. Pharmacological characterization of the seven human NOX isoforms and their inhibitors. *Redox Biol.* **2019**, *26*, 101272. [CrossRef] [PubMed]

445. Schröder, K.; Wandzioch, K.; Helmcke, I.; Brandes, R.P. Nox4 Acts as a Switch Between Differentiation and Proliferation in Preadipocytes. *Arterioscler. Thromb. Vasc. Biol.* **2009**, *29*, 239–245. [CrossRef] [PubMed]

446. Barton, M.; Haas, E.; Bhattacharya, I. Getting Radical About Obesity New Links Between Fat and Heart Disease. *Arterioscler. Thromb. Vasc. Biol.* **2009**, *29*, 447–448. [CrossRef] [PubMed]

447. Wautier, M.-P.; Chappey, O.; Corda, S.; Stern, D.M.; Schmidt, A.M.; Wautier, J.-L. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. *Am. J. Physiol. Endocrinol. Metab.* **2001**, *280*, E685–E694. [CrossRef]